Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner

Atherosclerosis--an inflammatory disease

Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725 · see citing works

Standards of Medical Care in Diabetes—2012

(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240 · see citing works

Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus

Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., Skatchkov, M. P., Thaiss, F., Stahl, R. A. K., Warnholtz, A., et al. (2001) · Circulation Research · doi:10.1161/01.res.88.2.e14 · Cited by 1,176 · see citing works

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · see citing works

Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus

Guzik, T. J., Mussa, S., Gastaldi, D., Sadowski, J., Ratnatunga, C., Pillai, R. G., & Channon, K. M. (2002) · Circulation · doi:10.1161/01.cir.0000012748.58444.08 · Cited by 979 · see citing works

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · see citing works

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · see citing works

Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus

Heitzer, T., Krohn, K., Albers, S., & Meinertz, T. (2000) · Diabetologia · doi:10.1007/s001250051551 · Cited by 427 · see citing works

Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery by Doppler echocardiography

Hozumi, T., Yoshida, K., Akasaka, T., Asami, Y., Ogata, Y., Takagi, T., Kaji, S., Kawamoto, T., Ueda, Y., & Morioka, S. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00389-1 · Cited by 425 · see citing works

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416 · see citing works

Tetrahydrobiopterin-dependent preservation of nitric oxide–mediated endothelial function in diabetes by targeted transgenic GTP–cyclohydrolase I overexpression

Alp, N. J., Mussa, S., Khoo, J. P., Cai, S., Guzik, T. J., Jefferson, A., Goh, N., Rockett, K. A., & Channon, K. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17786 · Cited by 321 · see citing works

Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor

Erdogdu, Ö., Nathanson, D., Sjöholm, Å., Nyström, T., & Zhang, Q. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.022 · Cited by 229 · see citing works

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride

Basu, A., Charkoudian, N., Schrage, W., Rizza, R. A., Basu, R., & Joyner, M. J. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00373.2007 · Cited by 226 · see citing works

Rapid, Direct Effects of Statin Treatment on Arterial Redox State and Nitric Oxide Bioavailability in Human Atherosclerosis via Tetrahydrobiopterin-Mediated Endothelial Nitric Oxide Synthase Coupling

Antoniades, C., Bakogiannis, C., Leeson, P., Guzik, T. J., Zhang, M.-H., Tousoulis, D., Antonopoulos, A. S., Demosthenous, M., Marinou, K., Hale, A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.985150 · Cited by 219 · see citing works

Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus

Ratner, R. E., Maggs, D., Nielsen, L. L., Stonehouse, A. H., Poon, T., Zhang, B., Bicsak, T. A., Brodows, R. G., & Kim, D. D. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00589.x · Cited by 217 · see citing works

Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes

Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204 · see citing works

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE -/- mouse model

Gaspari, T. A., Liu, H., Welungoda, I., Hu, Y., Widdop, R. E., Knudsen, L. B., Simpson, R. W., & Dear, A. E. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111404257 · Cited by 203 · see citing works

Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide–Dependent Mechanism

Chai, W., Dong, Z., Wang, N., Wang, W., Tao, L., Cao, W., & Liu, Z. (2012) · Diabetes · doi:10.2337/db11-1073 · Cited by 194 · see citing works

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

Liu, H., Dear, A. E., Knudsen, L. B., & Simpson, R. W. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0468 · Cited by 187 · see citing works

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism

Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097554 · Cited by 186 · see citing works

Homocysteine induces oxidative stress by uncoupling of no synthase activity through reduction of tetrahydrobiopterin

Topal, G., Brunet, A., Brussel, E. M., Boucher, J., Rendu, F., Devynck, M., & David‐Dufilho, M. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.03.019 · Cited by 167 · see citing works

Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells

CAI, S., Khoo, J., & Channon, K. M. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.10.040 · Cited by 165 · see citing works

Non-invasive assessment of coronary flow and coronary flow reserve by transthoracic Doppler echocardiography: a magic tool for the real world

Meimoun, P., & Tribouilloy, C. (2008) · European Journal of Echocardiography · doi:10.1093/ejechocard/jen004 · Cited by 118 · see citing works

Acute Inhibition of Guanosine Triphosphate Cyclohydrolase 1 Uncouples Endothelial Nitric Oxide Synthase and Elevates Blood Pressure

Wang, S., Xu, J., Song, P., Wu, Y., Zhang, J., Choi, H. C., & Zou, M. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.112094 · Cited by 110 · see citing works

GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation

Cai, S. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00460-1 · Cited by 105 · see citing works

Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways

Erdogdu, Ö., Eriksson, L., Xu, H. X., Sjöholm, Å., Zhang, Q., & Nyström, T. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0166 · Cited by 74 · see citing works

Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research

Irace, C., Luca, S. D., Shehaj, E., Carallo, C., Loprete, A., Scavelli, F. B., & Gnasso, A. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112449562 · Cited by 72 · see citing works

Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia

He, L., Zeng, H., Li, F., Feng, J., Liu, S., Liu, J., Yu, J., Mao, J., Hong, T., Chen, A. F., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00367.2010 · Cited by 62 · see citing works

The effect of liraglutide on endothelial function in patients with type 2 diabetes

Nandy, D. K., Johnson, C., Basu, R., Joyner, M. J., Brett, J., Svendsen, C. B., & Basu, A. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114547358 · Cited by 56 · see citing works

Liraglutide ameliorates renal injury in streptozotocin-induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor-κB pathway

Zhou, S., Bai, L., Lv, L., Chen, R., Li, C., LIU, X.-Y., Yu, D. M., & Yu, P. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2555 · Cited by 51 · see citing works

Glucagon-like peptide-1 protects the murine hippocampus against stressors via Akt and ERK1/2 signaling

Yoshino, Y., Ishisaka, M., Tsujii, S., Shimazawa, M., & Hara, H. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.098 · Cited by 34 · see citing works

Do incretins improve endothelial function?

Oyama, J., Higashi, Y., & Node, K. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-21 · Cited by 28 · see citing works

Cardiovascular Effects of Incretins in Diabetes

Advani, A., Bugyei‐Twum, A., & Connelly, K. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.06.010 · Cited by 23 · see citing works

PPAR-αAgonist Fenofibrate Upregulates Tetrahydrobiopterin Level through Increasing the Expression of Guanosine 5′-Triphosphate Cyclohydrolase-I in Human Umbilical Vein Endothelial Cells

Liu, J., Lu, C., Li, F., Wang, H., He, L., Hao, Y., Chen, A. F., An, H., Wang, X., Hong, T., et al. (2011) · PPAR Research · doi:10.1155/2011/523520 · Cited by 21 · see citing works

Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Agonist Improves Coronary Artery Endothelial Function in Diabetic Patients with Coronary Artery Disease

Yu, J., Zhang, Z., Li, Z., Feng, X., He, L., Liu, S., Mao, J., Wang, G. A., & Wang, X. (2010) · Journal of International Medical Research · doi:10.1177/147323001003800110 · Cited by 20 · see citing works

Incretins and Preservation of Endothelial Function

Koška, J. (2012) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152512803530289 · Cited by 19 · see citing works

Coronary Flow Velocity Reserve is Improved by PPAR‐α Agonist Fenofibrate in Patients with Hypertriglyceridemia

Wang, G., He, L., Liu, J., Yu, J., Feng, X., Li, F., Hao, Y., Mao, J., Hong, T., Chen, A. F., et al. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2011.00307.x · Cited by 18 · see citing works

Low density lipoprotein cholesterol level inversely correlated with coronary flow velocity reserve in patients with Type 2 diabetes.

Yu, J., Han, J., He, L., Feng, X.-H., Li, W., Mao, J., Gao, W., & Wang, G. (2013) · Europe PMC (PubMed Central) · doi:10.3969/j.issn.1671-5411.2013.02.007 · Cited by 12 · see citing works

Correlation between arterial stiffness and coronary flow velocity reserve in subjects with pulse wave velocity >1400 cm/s

Liu, J., Wang, Y., An, H., Liu, J., Wei, J., Wang, H., & Wang, G. (2015) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2015.1060988 · Cited by 8 · see citing works

Untitled work

Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7

GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art

Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · see citing works

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582 · see citing works

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways

Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509 · see citing works

Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications

Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358 · see citing works

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential

Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299 · see citing works

Emerging Role of cAMP/AMPK Signaling

Aslam, M., & Ladilov, Y. (2022) · Cells · doi:10.3390/cells11020308 · Cited by 241 · see citing works

International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases

Dessauer, C. W., Watts, V. J., Ostrom, R. S., Conti, M., Dove, S., & Seifert, R. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013078 · Cited by 201 · see citing works

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171 · see citing works

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6

Nauck, M. A., & Quast, D. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645566 · Cited by 112 · see citing works

Role of PI3K in the Progression and Regression of Atherosclerosis

Zhao, Y., Qian, Y., Sun, Z., Shen, X., Cai, Y., Li, L., & Wang, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.632378 · Cited by 98 · see citing works

Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options

Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98 · see citing works

Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction

Qin, Q., Delrio, S., Wan, J., Widmer, R. J., Cohen, P., Lerman, L. O., & Lerman, A. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.001 · Cited by 95 · see citing works

Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats

Candeias, E., Sebastião, I., Cardoso, S., Carvalho, C., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Duarte, A. I. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0622-3 · Cited by 88 · see citing works

Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output

Liu, J., Yang, K., Yang, J., Xiao, W., Le, Y., Yu, F., Gu, L., Lang, S., Tian, Q., Jin, T., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.037 · Cited by 85 · see citing works

Exendin‐4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant

Yap, M. K. K., & Misuan, N. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13169 · Cited by 77 · see citing works

Coffee and Endothelial Function: A Coffee Paradox?

Higashi, Y. (2019) · Nutrients · doi:10.3390/nu11092104 · Cited by 75 · see citing works

GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far

Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68 · see citing works

The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms

Ribeiro-Silva, J. C., Tavares, C. A. M., & Girardi, A. C. C. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102355 · Cited by 71 · see citing works

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms

Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72 · see citing works

AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases

Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69 · see citing works

Exendin-4 inhibits structural remodeling and improves Ca 2+ homeostasis in rats with heart failure via the GLP-1 receptor through the eNOS/cGMP/PKG pathway

Chen, J., Wang, D., Wang, F., Shi, S., Chen, Y., Yang, B., Tang, Y., & Huang, C. (2017) · Peptides · doi:10.1016/j.peptides.2017.02.008 · Cited by 62 · see citing works

Therapeutic application of GPR119 ligands in metabolic disorders

Yang, J. W., Kim, H. S., Choi, Y., Kim, Y., & Kang, K. W. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13062 · Cited by 62 · see citing works

Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease

Caruso, P., Maiorino, M. I., Longo, M., Porcellini, C., Matrone, R., Selvaggio, L. D., Gicchino, M., Carbone, C., Scappaticcio, L., Bellastella, G., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.1545 · Cited by 61 · see citing works

Treatment of Obesity in Mitigating Metabolic Risk

Heffron, S. P., Parham, J. S., Pendse, J., & Alemán, J. O. (2020) · Circulation Research · doi:10.1161/circresaha.119.315897 · Cited by 59 · see citing works

A GLP-1 analog lowers ER stress and enhances protein folding to ameliorate homocysteine-induced endothelial dysfunction

Cheng, C. K., Luo, J., Lau, C. W., Cho, W. C. S., Ng, C., Ronald, C. W., Tian, X. Y., & Huang, Y. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00589-x · Cited by 58 · see citing works

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)

Hullon, D., Subeh, G. K., Volkova, Y., Janiec, K., Trach, A., & Mnevets, R. O. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02607-w · Cited by 58 · see citing works

Exendin-4 ameliorates high glucose-induced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells

Jia, Y., Zheng, Z., Guan, M., Zhang, Q., Yang, L., Wang, L., & Xue, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0084-3 · Cited by 55 · see citing works

Vascular (dys)function in the failing heart

Liberale, L., Duncker, D. J., Hausenloy, D. J., Kraler, S. C., Bøtker, H. E., Podesser, B. K., Heusch, G., & Kleinbongard, P. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01163-w · Cited by 55 · see citing works

The metabolite GLP‐1 (9‐36) is neuroprotective and anti‐inflammatory in cellular models of neurodegeneration

Li, Y., Glotfelty, E. J., Karlsson, T. E., Fortuno, L. V., Harvey, B. K., & Greig, N. H. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15521 · Cited by 47 · see citing works

The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health

Qassab, M. A., Mneimneh, M., Jradi, A., Derbas, B., Dabboussi, D., Baini, J. K., Katrib, N., Chaarani, N., Attieh, P., Kanaan, A., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040285 · Cited by 52 · see citing works

AMPK pathway: an emerging target to control diabetes mellitus and its related complications

Kakoti, B. B., Alom, S., Deka, K., & Halder, R. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01420-8 · Cited by 47 · see citing works

Fucoidan ameliorates pancreatic β‐cell death and impaired insulin synthesis in streptozotocin‐treated β cells and mice via a Sirt‐1‐dependent manner

Yu, W., Chen, Y., Hwang, P., Chen, T., & Chou, T. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700136 · Cited by 44 · see citing works

Exenatide exhibits anti‐inflammatory properties and modulates endothelial response to tumor necrosis factor α‐mediated activation

Garczorz, W., Gallego-Colón, E., Kosowska, A., Kłych‐Ratuszny, A., Woźniak, M., Marcol, W., Niesner, K. J., & Francuz, T. (2017) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12317 · Cited by 43 · see citing works

Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms

Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 43 · see citing works

Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities

Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 42 · see citing works

The role of glucagon‐like peptide‐1 receptor agonists in metabolic dysfunction‐associated steatohepatitis

Abdelmalek, M. F., Harrison, S. A., & Sanyal, A. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15524 · Cited by 43 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice

Mori, Y., Kushima, H., Koshibu, M., Saito, T., Hiromura, M., Kohashi, K., Terasaki, M., Seino, Y., Yamada, Y., & Hirano, T. (2018) · Endocrinology · doi:10.1210/en.2018-00336 · Cited by 39 · see citing works

Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway

Ke, J., Liu, Y., Yang, J., Lu, R., Tian, Q., Hou, W., Wang, G., Wei, R., & Hong, T. (2017) · Scientific Reports · doi:10.1038/srep41085 · Cited by 38 · see citing works

Incretin drugs as modulators of atherosclerosis

Gallego-Colon, E., Wojakowski, W., & Francuz, T. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.011 · Cited by 35 · see citing works

GLP-1 Receptor Agonists and Myocardial Perfusion: Bridging Mechanisms to Clinical Outcomes

Karakasis, P., Patoulias, D., Theofilis, P., Pamporis, K., Sagris, Μ., Vlachakis, P. K., Koufakis, T., Antoniadis, A. P., & Fragakis, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073050 · Cited by 36 · see citing works

Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes

Lyu, J., Imachi, H., Fukunaga, K., Sato, S., Kobayashi, T., Dong, T., Saheki, T., Matsumoto, M., Iwama, H., Zhang, H., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.12.015 · Cited by 36 · see citing works

GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance

Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35 · see citing works

Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists

Wu, Q., Li, D., Huang, C., Zhang, G., Wang, Z., Liu, J., Yu, H., Song, B., Zhang, N., Li, B., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113517 · Cited by 31 · see citing works

Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?

Bakbak, E., Terenzi, D. C., Trac, J. Z., Teoh, H., Quan, A., Glazer, S. A., Rotstein, O. D., Al-Omran, M. A., Verma, S., & Hess, D. A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09669-7 · Cited by 30 · see citing works

Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients

Correale, M., Lamacchia, O., Ciccarelli, M., Dattilo, G., Tricarico, L., & Brunetti, N. D. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10157-y · Cited by 29 · see citing works

Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists

Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 33 · see citing works

GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review

Jarade, C., Zolotarova, T., Moiz, A., & Eisenberg, M. J. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102789 · Cited by 29 · see citing works

Liraglutide ameliorates palmitate-induced oxidative injury in islet microvascular endothelial cells through GLP-1 receptor/PKA and GTPCH1/eNOS signaling pathways

Le, Y., Wei, R., Yang, K., Lang, S., Gu, L., Liu, J., Hong, T., & Yang, J. (2019) · Peptides · doi:10.1016/j.peptides.2019.170212 · Cited by 28 · see citing works

Therapeutic potential of GLP-1 receptor agonists in diabetes and cardiovascular disease: mechanisms and clinical implications

Zhang, X., Cao, C., Zheng, F., Liu, C., & Tian, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07670-9 · Cited by 27 · see citing works

Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease

Wang, T., Ding, J., Cheng, X., Yang, Q., & Hu, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1396656 · Cited by 29 · see citing works

Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes

Aung, M. M., Slade, K., Freeman, L. A. R., Kos, K., Whatmore, J. L., Shore, A. C., & Gooding, K. M. (2019) · Diabetologia · doi:10.1007/s00125-019-4918-x · Cited by 27 · see citing works

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Chen, X., Zhang, X., Xiang, X., Fang, X., & Feng, S. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01497-4 · Cited by 26 · see citing works

Mechanistic insights and emerging therapeutic strategies targeting endothelial dysfunction in cardiovascular diseases

Heo, K., Phan, L. P., Le, N. T. T., & Jin, Y. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01542-4 · Cited by 29 · see citing works

Glucagon-like peptide-1 receptor agonists and the endothelium: molecular and clinical insights into cardiovascular protection

Battistoni, A., Piras, L., Tartaglia, N., Carrano, F. M., Vitis, C. D., & Barbato, E. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1669685 · Cited by 30 · see citing works

Liraglutide, a Glucagon-like Peptide-1 Receptor Agonist, Attenuates Development of Cardiac Allograft Vasculopathy in a Murine Heart Transplant Model

Wang, Z., Wang, M., Hu, X.-F., Li, Y., Ma, D., Li, S.-L., Zhao, G., Xie, Y., Shu, Y., & Yang, J. (2018) · Transplantation · doi:10.1097/tp.0000000000002448 · Cited by 26 · see citing works

HFpEF and MASLD: converging mechanisms and clinical implications

Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 31 · see citing works

The potential role of Tirzepatide as adjuvant therapy in countering colistin-induced nephro and neurotoxicity in rats via modulation of PI3K/p-Akt/GSK3-β/NF-kB p65 hub, shielding against oxidative and endoplasmic reticulum stress, and activation of p-CREB/BDNF/TrkB cascade

Hassan, N. F., Ragab, D., Ibrahim, S. G., Elgalil, M. M. A., Abd-El-Hamid, A. H., Hamed, D. M., William, M. M., & Salem, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112308 · Cited by 24 · see citing works

When Good Guys Turn Bad: Bone Marrow’s and Hematopoietic Stem Cells’ Role in the Pathobiology of Diabetic Complications

Vinci, M. C., Gambini, E., Bassetti, B., Genovese, S., & Pompilio, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113864 · Cited by 24 · see citing works

Liraglutide restores angiogenesis in palmitate-impaired human endothelial cells through PI3K/Akt-Foxo1-GTPCH1 pathway

Ke, J., Wei, R., Yu, F., Zhang, J., & Hong, T. (2016) · Peptides · doi:10.1016/j.peptides.2016.10.009 · Cited by 24 · see citing works

Exendin-4 Preserves Blood-Brain Barrier Integrity via Glucagon-Like Peptide 1 Receptor/Activated Protein Kinase-Dependent Nuclear Factor-Kappa B/Matrix Metalloproteinase-9 Inhibition After Subarachnoid Hemorrhage in Rat

Xie, Z., Enkhjargal, B., Matei, N., Wu, L., Zhu, Q., Zhang, T., Tang, J., & Zhang, J. H. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.750726 · Cited by 23 · see citing works

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity

Yazıcı, D., Eser, H. Y., Kiyici, S. K., Sancak, S., Sezer, H., Uygur, M., & Yumuk, V. (2022) · Obesity Facts · doi:10.1159/000526808 · Cited by 21 · see citing works

Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists

Ji, Q. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.013 · Cited by 21 · see citing works

The Effects of Exenatide and Metformin on Endothelial Function in Newly Diagnosed Type 2 Diabetes Mellitus Patients: A Case–Control Study

Hu, Y., Liu, J., Wang, G., & Xu, Y. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0435-z · Cited by 21 · see citing works

Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction

Suhrs, H. E., Raft, K. F., Bove, K. B., Madsbad, S., Holst, J. J., Zander, M., & Prescott, E. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.12.005 · Cited by 21 · see citing works

A primer on obesity-related cardiomyopathy

Samson, W. K., Yosten, G. L. C., & Remme, C. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00023.2021 · Cited by 21 · see citing works

Glucagon-like peptide-1 receptor activation maintains extracellular matrix integrity by inhibiting the activity of mitogen-activated protein kinases and activator protein-1

Peng, Y., Lin, H., Tian, S., Liu, S., Li, J., Lv, X., Chen, S., Zhao, L., Pu, F., Chen, X., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.10.034 · Cited by 19 · see citing works

Effects of L-arginine supplementation on fat deposition and meat quality in growing lambs: Interactions with gut microbiota and metabolic signalling pathways

Kang, L., Li, X., Zhao, X., Liu, T., Jin, Y., & Duan, Y. (2025) · Food Chemistry · doi:10.1016/j.foodchem.2025.143677 · Cited by 18 · see citing works

Liraglutide Accelerates Ischemia‐Induced Angiogenesis in a Murine Diabetic Model

Zhu, Y., Li, Y., Ma, Y., Zhang, X., Du, X., Gao, J., Ding, N., Wang, L., Ni, C., Luo, M., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.026586 · Cited by 18 · see citing works

Ethyl Rosmarinate Protects High Glucose-Induced Injury in Human Endothelial Cells

Shen, Y., Wang, L., Zhang, B., Hu, Q.-M., Wang, P., He, B.-Q., Bao, G., Liang, J., & Wu, F. (2018) · Molecules · doi:10.3390/molecules23123372 · Cited by 17 · see citing works

Effect of eNOS on Ischemic Postconditioning-Induced Autophagy against Ischemia/Reperfusion Injury in Mice

Shao, J., Miao, C., Geng, Z., Gu, M.-H., Wu, Y., & Li, Q. (2019) · BioMed Research International · doi:10.1155/2019/5201014 · Cited by 17 · see citing works

A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis

Jin, L., Sun, Y., Li, Y., Zhang, H., Yu, W., Li, Y., Xin, Y., Alsareii, S. A., Wang, Q., & Zhang, D. (2021) · Peptides · doi:10.1016/j.peptides.2021.170597 · Cited by 17 · see citing works

Remote ischemic conditioning protects against endothelial ischemia-reperfusion injury via a glucagon-like peptide-1 receptor-mediated mechanism in humans

Verouhis, D., Saleh, N., Settergren, M., Sörensson, P., Gourine, A. V., & Pernow, J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.09.061 · Cited by 16 · see citing works

Microvascular Density and Circulating Endothelial Progenitor Cells Before and After Treatment with Incretin Mimetics in Diabetic Patients

Ciuceis, C. D., Rosei, C. A., Rossini, C., Caletti, S., Coschignano, M. A., Ferrari‐Toninelli, G., Ragni, G., Cappelli, C., Cerudelli, B., Airó, P., et al. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0279-7 · Cited by 16 · see citing works

GLP-1/GLP-1R axis: from metabolism (obesity and T2DM) to immunity

Kumar, V. (2025) · Open Biology · doi:10.1098/rsob.240303 · Cited by 15 · see citing works

Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance

Hardoňová, M., Šiarnik, P., Siváková, M., Sucha, B., Penesová, A., Rádiková, Ž., Havranová, A., Imrich, R., Vlček, M., Žitňanová, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311162 · Cited by 15 · see citing works

Glucagon-like Peptide-1 Receptor Agonists

Jeon, J. Y., & Kim, H. J. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_14 · Cited by 15 · see citing works

Pleiotropic effects of GLP‐1 receptor agonists on peripheral artery disease: Is there any hope?

Caruso, P., Maiorino, M. I., Bellastella, G., Esposito, K., & Giugliano, D. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3627 · Cited by 14 · see citing works

Sitagliptin Accelerates Endothelial Regeneration after Vascular Injury Independent from GLP1 Receptor Signaling

Remm, F., Kränkel, N., Lener, D., Drucker, D. J., Sopper, S., & Brenner, C. (2018) · Stem Cells International · doi:10.1155/2018/5284963 · Cited by 14 · see citing works

Molecular damage associated with ageing drives inflammation in cardiovascular disease

Herman, A. B., Candia, J., Wilson, D., Donegà, S., Picard, M. A., & Ferrucci, L. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01253-3 · Cited by 14 · see citing works

Evaluation of glucagon-like peptide-1 receptor expression in nondiabetic and diabetic atherosclerotic mice using PET tracer 68Ga-NODAGA-exendin-4

Ståhle, M. R., Hellberg, S., Virta, J., Liljenbäck, H., Metsälä, O., Li, X., Jauhiainen, M., Saukko, P. J., Ylä‐Herttuala, S., Nuutila, P., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00465.2020 · Cited by 12 · see citing works

An updated review on therapeutic strategies in coronary microvascular dysfunction

Khandkar, C., Rehan, R., Ravindran, J., & Yong, A. S. C. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133128 · Cited by 12 · see citing works

Intermedin protects peritubular capillaries by inhibiting eNOS uncoupling through AMPK/GTPCH-I/BH4 pathway and alleviate CKD following AKI

Lin, H., Pan, J., Zhang, J., He, Y., Yuan, G., Niu, D., Han, W., Han, X., Fan, L., Bai, X., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.04.015 · Cited by 11 · see citing works

Madagascine Induces Vasodilatation via Activation of AMPK

Chen, D., Lv, B., Kobayashi, S., Xiong, Y., Sun, P., Lin, Y., Genovese, S., Epifano, F., Hou, S., Tang, F., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00435 · Cited by 11 · see citing works

Non-targeted metabolomic analysis predicts the therapeutic effects of exenatide on endothelial injury in patients with type 2 diabetes

Yang, J., Le, Y., Wei, T., Wang, K., Yang, K., Xiao, W., Hong, T., & Wei, R. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107797 · Cited by 10 · see citing works

Cardiovascular effects of antiobesity drugs: are the new medicines all the same?

Cataldi, M., Cignarelli, A., Giallauria, F., Muscogiuri, G., Barrea, L., Savastano, S., & Colao, A. A. L. (2020) · International Journal of Obesity Supplements · doi:10.1038/s41367-020-0015-3 · Cited by 10 · see citing works

Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan‐L trial

Giorgino, F., Shaunik, A., Liu, M., & Saremi, A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13857 · Cited by 10 · see citing works

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults

Nilsson, M., Bove, K. B., Suhrs, H. E., Hermann, T. S., Madsbad, S., Holst, J. J., Prescott, E., & Zander, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.01.004 · Cited by 10 · see citing works

Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients

Madsbad, S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1615444 · Cited by 10 · see citing works

GLP-1R agonist therapy and vaccine response: Neglected implications

van Niekerk, G., Coelmont, L., Alpizar, Y. A., Kelchtermans, L., Broeckhoven, E., & Dallmeier, K. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.07.006 · Cited by 9 · see citing works

Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide

Odigwe, C. I., Mulyala, R. R., Malik, H., Ruiz, B., Riad, M., Sayiadeh, M. A., Honganur, S., Parks, A., Rahman, M. U., & Lakkis, N. M. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100518 · Cited by 9 · see citing works

Outcomes of GLP-1 receptor agonist use following ischemic stroke: a propensity score-matched real-world analysis

Rai, P., Bathla, G., Praveen, N., Gopikonda, S. S., Chen, H. A., Salim, H. A., Azzam, A. Y., Essibayi, M. A., Altschul, D., Dmytriw, A. A., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13470-w · Cited by 9 · see citing works

Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease

Bernardini, F., Nusca, A., Coletti, F., Porta, Y. L., Piscione, M., Vespasiano, F., Mangiacapra, F., Ricottini, E., Melfi, R., Cavallari, I., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071858 · Cited by 8 · see citing works

Obesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists

Tirandi, A., Montecucco, F., Carbone, F., & Liberale, L. (2024) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16658 · Cited by 8 · see citing works

Exendin‑4 reverses endothelial dysfunction in mice fed a high‑cholesterol diet by a GTP cyclohydrolase‑1/tetrahydrobiopterin pathway

Tang, Z., Liu, L., Guo, Y., Deng, G., Chen, M., & Wei, J. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9345 · Cited by 8 · see citing works

Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists

Song, R., Qian, H., Wang, Y., Li, Q., Li, D., Chen, J., Yang, J., Zhong, J., Yang, H., Min, X., et al. (2022) · Journal of Diabetes Research · doi:10.1155/2022/4554996 · Cited by 8 · see citing works

Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure

Llongueras-Espí, P., García‐Romero, E., Colet, J. C., & González‐Costello, J. (2025) · Biomolecules · doi:10.3390/biom15091342 · Cited by 7 · see citing works

Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors

Bostrom, J., Mottel, B. H., & Heffron, S. P. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00961-0 · Cited by 7 · see citing works

The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease

Guo, Z. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00609-1 · Cited by 6 · see citing works

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans

Koska, J., Sands, M., Burciu, C., D’Souza, K. M., Raravikar, K., Liu, J., Truran, S., Franco, D. A., Schwartz, E. A., Schwenke, D. C., et al. (2015) · Diabetes · doi:10.2337/db14-0976 · Cited by 174 · see citing works

Role of GLP-1 receptor agonists in endothelial function

Erdogdu, Ö. (2012) · Figshare

[Effects of GLP-1 Agonist Exenatide on Cardiac Diastolic Function and Vascular Endothelial Function in Diabetic Patients].

Wang, X.-H., Han, L.-N., Yu, Y., Wang, C., Wang, B., Wen, X., Huang, H., & Jing, X. (2015) · PubMed · Cited by 7 · see citing works

Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo

Nathanson, D., Erdogdu, Ö., Pernow, J., Zhang, Q., & Nyström, T. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.07.003 · Cited by 51 · see citing works

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus

Torimoto, K., Okada, Y., Mori, H., Otsuka, T., Kawaguchi, M., Matsuda, M., Kuno, F., Sugai, K., Sonoda, S., Hajime, M., et al. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0188-1 · Cited by 43 · see citing works